I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.
Dated: September 7, 2005 Signature: (Mary Jane D'Alma)

Docket No.: ASZD-P01-804
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Barton et al.

Application No.: 10/522225 Confirmation No.: 7196

Filed: January 24, 2005 Art Unit: 1645

For: KETONES Examiner: Not Yet Assigned

REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicants, a copy of which is attached hereto, has the following errors:

In the Heading:

Under "FIL FEE REC'D" delete "1710" and instead insert --2010--;

Under "TOT CLMS" delete "16" and instead insert --20--.

In the applicant(s) section:

In addition to Peter John Barton, Macclesfield, GBN, United Kingdom; and David Stephen Clarke, Macclesfield, GBN, United Kingdom, please add the following applicants:

Christopher Daniel Davies, Macclesfield, GBN, United Kingdom;

Rodney Brian Hargreaves, Macclesfield, GBN, United Kingdom;

Janet Elizabeth Pease, Macclesfield, GBN, United Kingdom; and

Maureen Theresa Rankine, Macclesfield, GBN, United Kingdom.

In the title:

Please delete "Chemical compounds" and instead insert the correct title --Ketones--.

Serial No. 10/522225 Attorney Docket No.: ASZD-P01-804

The correct Filing Fee should be $2010.00 as show on the enclosed copy of the Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission under 35 U.S.C. 371 that was filed with the application on January 24, 2005. The total claim count is 20 as shown on the enclosed copy of the Preliminary Amendment that was filed with the application on January 24, 2005. The correct applicants and title are noted on the enclosed copy of the executed Combined Declaration and Power of Attorney that was filed with the application on January 24, 2005. Applicants additionally request that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect these corrections.

Please charge our Deposit Account No. 18-1945 in the amount of $300.00, which is the difference in the USPTO filing fee charge ($1710.00) and the actual fee due ($2,010.00), under Order No. ASZD-P01-804 for the from which the undersigned is authorized to draw. A duplicate copy of this paper is enclosed.

Dated: September 7, 2005

Respectfully submitted,

By _____

David P. Halstead, Ph.D.
Registration No.: 44,735
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/522,225	01/24/2005	1645	~~1710~~ 2,010.00	ASZD-P01-804		~~18~~ 20	4

CONFIRMATION NO. 7196

28120
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
ONE INTERNATIONAL PLACE
BOSTON, MA 02110-2624

FILING RECEIPT

OC000000016718976

Date Mailed: 08/17/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Peter John Barton, Macclesfield, GBN, UNITED KINGDOM;
David Stephen Clarke, Macclesfield, GBN, UNITED KINGDOM;
Christopher Daniel Davies, Macclesfield, GBN, UK;
Rodney Brian Hargreaves, Macclesfield, GBN, UK;
Janet Elizabeth Pease, Macclesfield, GBN, UK; Maureen Theresa Rankine, Macclesfield, GBN, UK

Power of Attorney: The patent practitioners associated with Customer Number **28120**.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/03171 07/23/2003

Foreign Applications

UNITED KINGDOM 0217433.2 07/27/2002
UNITED KINGDOM 0230318.8 12/24/2002

Ropes & Gray
Symbol #: ASZD-P01-804
Action Due: RVW | File Corr FR
Deadline(s): Sept 17.

Projected Publication Date: 11/17/2005

Non-Publication Request: No

Early Publication Request: No

Ropes & Gray
AUG 22 2005
Intellectual Property Dept.

Title

~~Chemical compounds~~
KETONES

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to esplonage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PTO-1390 (Rev. 12-2004)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	ASZD-P01-804
U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB2003/003171	23 July 2003	27 July 2002

TITLE OF INVENTION KETONES

APPLICANT(S) FOR DO/EO/US Barton et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [x] This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. [x] This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. [X] The US has been elected (Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
   a. [ ] is attached hereto (required only if not communicated by the International Bureau).
   b. [x] has been communicated by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [ ] An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
   a. [ ] is attached hereto.
   b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. [ ] are attached hereto (required only if not communicated by the International Bureau).
   b. [ ] have been communicated by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [x] have not been made and will not be made.
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. [ ] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. [X] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A preliminary amendment.
14. [X] An Application Data Sheet under 37 CFR 1.76.
15. [ ] A substitute specification.
16. [ ] A power of attorney and/or change of address letter.
17. [ ] A computer-readable form of the sequence listing in accordance with PCT Rule 13*ter*.2 and 37 CFR 1.821 - 1.825.
18. [X] A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. [X] Other items or information: Return Receipt Postcard

PTO-1390 (Rev. 12-2004)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO. PCT/GB2003/003171	ATTORNEY'S DOCKET NUMBER ASZD-P01-804

21. The following fees are submitted:	Applicant Use	Office Use Only
[x] a) Basic national fee $300.00	$ 300.00	
[x] b) Examination fee $200.00	$ 200.00	
[x] c) Search fee $500.00	$ 500.00	
TOTAL OF ABOVE CALCULATIONS = $1000.00	$ 1,000.00	
[x] Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is $250 for each additional 50 sheets of paper or fraction thereof.		
Total Sheets: 145 - 100 = / Extra sheets: 45 / 50 = / Number of each additional 50 or fraction thereof (round up to a whole number): 1 / RATE: x $250.00	250.00	
Surcharge of $130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	$	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	24 - 20 =	4	x 50.00	$ 200.00	
Independent claims	4 - 3 =	1	x 200.00	$ 200.00	
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			+ 360.00	$ 360.00	
			TOTAL OF ABOVE CALCULATIONS =	$ 2,010.00	
[ ] Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				$	
			SUBTOTAL =	$ 2,010.00	
Processing fee of $130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).			+	$	
			TOTAL NATIONAL FEE =	$ 2,010.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property			+	$ 40.00	
			TOTAL FEES ENCLOSED =	$ 2,050.00	
			Amount to be refunded:		$
			Amount to be charged:		$

a. [ ] A check in the amount of $ _____ to cover the above fees is enclosed.

b. [x] Please charge my Deposit Account No. 18-1945 in the amount of $ 2,050.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [x] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 18-1945. A duplicate copy of this sheet is enclosed.

d. [ ] Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Patricia Granahan, Sc.D.
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7449
CUSTOMER NUMBER: 28120

SIGNATURE:
David P. Halstead, Ph.D.
NAME
44,735
REGISTRATION NUMBER

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV620562193US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 24, 2005 Signature: (Mary Jane DiPalma)

Docket No.: ASZD-P01-804
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Peter John Barton et al.

Application No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: January 24, 2005

Art Unit: Not Yet Assigned

For: Ketones

Examiner: Not Yet Assigned

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Please amend the above-identified application prior to substantive examination as follows:

Amendments to the specification begin on page 2 of this paper.

Amendments to the claims begin on page 3 of this paper.

Application No.: Not Yet Assigned Docket No.: ASZD-P01-804

In the Specification:

On Page 1, please insert the following paragraph immediately after the title:

Related Applications

This application is a national stage filing under 35 U.S.C. 371 of International Application PCT/GB2003/003171, filed July 23, 2003, which claims priority from United Kingdom Patent Applications Nos. 0217433.2, filed July 27, 2002 and 0230318.8, filed December 24, 2002, the specifications of all of which are incorporated by reference herein. International Application PCT/GB2003/003171 was published under PCT Article 21(2) in English.

Please insert the Abstract, appearing on a separate page herewith, immediately after the last page of the claims.

Application No.: Not Yet Assigned Docket No.: ASZD-P01-804

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for inhibiting 11βHSD1, comprising administering a compound of formula (I):



(I)

wherein:

Ring A is selected from aryl or heteroaryl;

R^1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-6}alkylene-Y-, and heterocyclylC_{0-6}alkylene-Y-; or two R^1 groups on adjacent carbons may form an oxyC_{1-4}alkoxy group or a C_{3-5}alkylene group; wherein R^1 may be optionally substituted on carbon ~~by~~ with one or more R^7 groups ~~selected from R^7~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^8 group ~~selected from R^8~~;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2, R^3, R^4, and R^5 are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, C_{1-4}alkoxycarbonylamino, C_{1-4}alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl; or R^2 and R^3 together form oxo or a spiro attached heterocyclyl; wherein R^2, R^3, R^4, and R^5 may be independently optionally substituted on carbon ~~by~~ with one or more R^9 groups ~~selected from R^9~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{10} group ~~selected from R^{10}~~;

X and **Z** are independently selected from $-CR^{11}R^{12}-$, $-S(O)_a-$, -O-, $-NR^{13}-$, -C(O)-, $-C(O)NR^{14}-$, $-NR^{15}C(O)-$, -OC(O)-, -C(O)O-, $-SO_2NR^{16}-$, ~~or~~ and $-NR^{16}SO_2-$; wherein a is 0 to 2;

r is 1 or 2;

q is 0 or 1;

p is 0 or 1;

s is 0 or 1;

Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by an R^{17} group ~~selected from R^{17}~~;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkyl$S(O)_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-4}alkylene-Y-, and heterocyclylC_{0-4}alkylene-Y-; wherein R^6 may be optionally substituted on carbon ~~by~~ with one or more R^{18} groups ~~selected from R^{18}~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{19} group ~~selected from R^{19}~~;

m is 0-3; wherein the values of R^6 may be the same or different;

Y is $-S(O)_a-$, -O-, $-NR^{20}-$, -C(O)-, $-C(O)NR^{21}-$, $-NR^{22}C(O)-$, or $-SO_2NR^{23}-$; wherein a is 0 to 2;

R^7, R^9, and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkyl$S(O)_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, and heterocyclyl; wherein R^7, R^9, and R^{18} may be independently optionally substituted on carbon ~~by~~ with one or more R^{26} groups;

R^{11} and R^{12} are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, carbocyclyl, heterocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl; wherein R^{11} and R^{12} may be independently

optionally substituted on carbon ~~by~~ with one or more R^{24} groups ~~selected from R^{24}~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{25} group ~~selected from R^{25}~~;

R^{24} is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, and C_{1-4}alkylsulphonylamino;

R^8, R^{10}, R^{17}, R^{19}, and R^{25} are independently selected from C_{1-4}alkyl, C_{1-4}alkanoyl, C_{1-4}alkylsulphonyl, C_{1-4}alkoxycarbonyl, carbamoyl, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl, and phenylsulphonyl; wherein R^8, R^{10}, R^{17}, R^{19}, and R^{25} may be independently optionally substituted on carbon ~~by~~ with one or more R^{27} groups;

R^{13}, R^{14}, R^{15}, R^{16}, R^{20}, R^{21}, R^{22}, and R^{23} are independently selected from hydrogen, phenyl, C_{1-4}alkylsulphonyl, and C_{1-4}alkyl;

R^{26} and R^{27} are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, and ~~or~~ *N*-methyl-*N*-ethylsulphamoyl;

or a pharmaceutically acceptable salt thereof;

~~in the manufacture of a medicament for use in the inhibition of 11βHSD1;~~

with the proviso that said compound is not (1-methyl-1-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone.

2. (Currently Amended) The method ~~use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in~~ of claim 1, wherein Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl, and ~~or~~ benzothienyl.

3. (Currently Amended) The method~~use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in either~~ of claim 1, ~~or claim 2~~ wherein R^1 is selected from halo, cyano, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkylsulphonylamino, carbocyclyl, and heterocyclylC_{0-6}alkylene-Y-; or two R^1 groups on adjacent carbons may form an oxyC_{1-4}alkoxy group; wherein R^1 may be optionally substituted on carbon ~~by~~ with one or more R^7 groups ~~selected from R^7~~;

Y is -S(O)$_a$-, or-O-; wherein a is 0 to 2; and

R^7 is halo.

4. (Currently Amended) The method~~use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one~~ of claims 1, [[-3]] wherein R^2, R^3, R^4, and R^5 are independently selected from hydrogen, hydroxy, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, carbocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl; wherein R^2, R^3, R^4, and R^5 may be independently optionally substituted on carbon ~~by~~ with one or more R^9 groups ~~selected from R^9~~; and~~wherein~~

R^9 is selected from halo, cyano, C_{1-4}alkyl, and *N,N*-(C_{1-4}alkyl)$_2$amino.

5. (Currently Amended) The method~~use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one~~ of claims 1, [[-6]] wherein X is -S(O)$_a$-, -O-, -NR^{13}-, -NR^{15}C(O)-, -SO$_2$NR^{16}-, or -NR^{16}SO$_2$-; wherein a is 0 or 2; and

R^{13}, R^{15}, and R^{16} are independently selected from hydrogen, phenyl, C_{1-4}alkylsulphonyl, and C_{1-4}alkyl.

6. (Currently Amended) The method~~use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one~~ of claims 1, [[-5]] wherein Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, 1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{17} group ~~selected from R^{17}~~;

R^{17} is C_{1-4}alkyl or benzyl; wherein R^{17} may be optionally substituted on carbon ~~by~~ with one or more R^{27} groups; ~~wherein~~and

R^{27} is methoxy.

7. (Currently Amended) The methoduse of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1,[[-6]] wherein R^6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 or 2, C_{1-4}alkoxycarbonyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, carbocyclyl, heterocyclyl, and carbocyclylC_{0-4}alkylene-Y-; wherein R^6 may be optionally substituted on carbon by with one or more R^{18} groups selected from R^{18}; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by with an R^{19} group selected from R^{19};

Y is -C(O) or -C(O)NR^{21}-;

R^{18} is selected from halo, cyano, hydroxy, C_{1-4}alkoxy, and heterocyclyl;

R^{19} is heterocyclyl; and

R^{21} is hydrogen.

8. (Currently Amended) The methoduse of a compound of formula (I) (as depicted in claim 1,[()]] wherein:

Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, imidazolyl, benzothiazolyl, and or benzothienyl;

R^1 is selected from halo, cyano, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkylsulphonylamino, carbocyclyl, and heterocyclylC_{0-6}alkylene-Y-; or two R^1 groups on adjacent carbons may form an oxyC_{1-4}alkoxy group; wherein R^1 may be optionally substituted on carbon by with one or more R^7 groups selected from R^7;

Y is -S(O)$_a$-, or-O-; wherein a is 0 to 2; and

R^7 is halo[[.]];

n is 0-3; wherein the values of R^1 may be the same or different;

r is 1 or 2;

s is 0;

R^2, R^3, R^4, and R^5 are independently selected from hydrogen, hydroxy, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, carbocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl;

wherein R^2, R^3, R^4, and R^5 may be independently optionally substituted on carbon ~~by~~ with one or more R^9 groups ~~selected from R^9~~; ~~wherein~~

R^9 is selected from halo, cyano, C_{1-4}alkyl, and *N,N*-(C_{1-4}alkyl)$_2$amino[[.]];

X is -$S(O)_a$-, -O-, -NR^{13}-, -$NR^{15}C(O)$-, -SO_2NR^{16}-, or -$NR^{16}SO_2$-; wherein a is 0 or 2; ~~and~~

R^{13}, R^{15}, and R^{16} are independently selected from hydrogen, phenyl, C_{1-4}alkylsulphonyl, and C_{1-4}alkyl;

q is 0 or 1;

p is 0 or 1;

Ring B is phenyl, thienyl, furyl, thiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, 1,3-dihydroisoindolyl, morpholinyl, naphthyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, 1,3-benzodioxolyl, thiomorpholinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, or pyrimidinyl; wherein if Ring B contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from R^{17};

R^{17} is C_{1-4}alkyl or benzyl; wherein R^{17} may be optionally substituted on carbon ~~by~~ with one or more R^{27} groups; ~~wherein~~

R^{27} is methoxy;

R^6 is a substituent on carbon and is selected from halo, hydroxy, nitro, cyano, carbamoyl, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 or 2, C_{1-4}alkoxycarbonyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, carbocyclyl, heterocyclyl, and carbocyclylC_{0-4}alkylene-Y-; wherein R^6 may be optionally substituted on carbon ~~by~~ with one or more R^{18} groups ~~selected from R^{18}~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{19} group ~~selected from R^{19}~~;

Y is -C(O) or -C(O)NR^{21}-;

R^{18} is selected from halo, cyano, hydroxy, C_{1-4}alkoxy, and heterocyclyl;

R^{19} is heterocyclyl; ~~and~~

R^{21} is hydrogen; and

m is 0-3; wherein the values of R^6 may be the same or different[[;]]

~~or a pharmaceutically acceptable salt thereof;~~

~~in the manufacture of a medicament for use in the inhibition of 11βHSD1;~~

~~with the proviso that said compound is not (1-methyl-1-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone~~.

9. (Currently Amended) A compound ~~of formula (I) (as depicted in claim 1)~~ selected from:
[2-(4-chlorophenyl)-1-(pyrid-3-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(4-chlorophenyl)-1-(pyrazin-2-yl)ethyl]-(pyridin-3-yl)-ketone;
(α-methylamino-4-chlorobenzyl)-(4-chlorophenyl)-ketone;
(benzothiazol-2-yl)-(pyrrolidin-1-ylsulphonylmethyl)-ketone;
(thiazol-2-yl)-(pyrrolidin-1-ylsulphonylmethyl)-ketone;
[1-(morpholinosulphonyl)-1-methylethyl]-(4-fluorophenyl)-ketone;
(4-fluorophenyl)-[*N*-(cyclohexyl)-*N*-(isopropyl)sulphamoylmethyl]-ketone;
(4-fluorophenyl)-[*N*-(pyrid-2-yl)-*N*-(methyl)sulphamoylmethyl]-ketone;
(4-methylphenylsulphonylmethyl)-(4-cyanophenyl)-ketone;
(4-ethoxyphenoxymethyl)-(4-chlorophenyl)-ketone;
(4-chlorophenyl)-[3-(2,6-difluorobenzoylamino) propyl)]-ketone; and
(4-chlorophenyl)-[3-(4-methoxyphenylsulphonylamino)propyl)]-ketone;
or a pharmaceutically acceptable salt thereof.

10. (Currently Amended) The <u>method</u>~~use of a compound~~ of ~~formula (I) (as depicted in~~ claim 1~~,[()]~~ <u>wherein the compound of formula (I) is</u> selected from:
(α-methyl-α-hydroxy-4-chlorobenzyl)-(4-chlorophenyl)-ketone;
(morpholinosulphonylmethyl)-(4-fluorophenyl)-ketone;
(*N*-methyl-4-methylanilinosulphonylmethyl)-(4-chlorophenyl)-ketone; and
(*N*-methyl-4-chloroanilinomethyl)-(4-chlorophenyl)-ketone;
or a pharmaceutically acceptable salt thereof[[;]]
~~in the manufacture of a medicament for use in the inhibition of 11βHSD1~~.

11. (Currently Amended) A compound of formula **(Ij)**:



(Ij)

wherein:

R^1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-6}alkylene-Y-, and heterocyclylC_{0-6}alkylene-Y-; or two R^1 groups on adjacent carbons may form an oxyC_{1-4}alkoxy group or a C_{3-5}alkylene group; wherein R^1 may be optionally substituted on carbon ~~by~~ with one or more R^7 groups ~~selected from R^7~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by an R^8 group ~~selected from R^8~~;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2 and R^3 are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, C_{1-4}alkoxycarbonylamino, C_{1-4}alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl; or R^2 and R^3 together form oxo or a spiro attached heterocyclyl; wherein R^2 and R^3 may be independently optionally substituted on carbon ~~by~~ with one or more R^9 groups ~~selected from R^9~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{10} group ~~selected from R^{10}~~;

Ring B is a heterocyclyl linked to the sulphonyl of the compound of formula **(Ij)** via a nitrogen atom; wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{17} group ~~selected from R^{17}~~;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-4}alkylene-Y-, and heterocyclylC_{0-4}alkylene-Y-; wherein R^6 may be optionally substituted on carbon ~~by~~ with one or more R^{18} groups ~~selected from R^{18}~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{19} group ~~selected from R^{19}~~;

m is 0-3; wherein the values of R^6 may be the same or different;

Y is $-S(O)_a-$, -O-, $-NR^{20}-$, -C(O)-, $-C(O)NR^{21}-$, $-NR^{22}C(O)-$, or $-SO_2NR^{23}-$; wherein a is 0 to 2;

R^7, R^9, and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkyl$S(O)_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, and heterocyclyl; wherein R^7, R^9, and R^{18} may be independently optionally substituted on carbon ~~by~~ with one or more R^{26} groups;

R^8, R^{10}, R^{17}, and R^{19} are independently selected from C_{1-4}alkyl, C_{1-4}alkanoyl, C_{1-4}alkylsulphonyl, C_{1-4}alkoxycarbonyl, carbamoyl, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl, and phenylsulphonyl; wherein R^8, R^{10}, R^{17}, and R^{19} may be independently optionally substituted on carbon ~~by~~ with one or more R^{27} groups;

R^{20}, R^{21}, R^{22}, and R^{23} are independently selected from hydrogen, phenyl, C_{1-4}alkylsulphonyl, and C_{1-4}alkyl;

R^{26} and R^{27} are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, and ~~or~~ *N*-methyl-*N*-ethylsulphamoyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not

(phenyl)-[α-(pyrrolidin-1-ylsulphonyl)benzyl]-ketone;

(phenyl)-[α-(morpholinosulphonyl)benzyl]-ketone;

(4-carbamoylphenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-1-ylsulphonylmethyl]-ketone;

(4-carbamoylphenyl)-[4-(4-fluorophenyl)piperidin-1-ylsulphonylmethyl]-ketone;

(4-fluorophenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-1-ylsulphonylmethyl]-ketone;
(phenyl)-[4-(5-chloropyridin-2-yloxy)piperidin-1-ylsulphonylmethyl]-ketone;
(4-chlorophenyl)-(piperazin-1-ylsulphonylmethyl)-ketone;
(4-chlorophenyl)-[4-(*t*-butoxycarbonyl)piperazin-1-ylsulphonylmethyl]-ketone;
(4-hydroxyphenyl)-(morpholinosulphonylmethyl)-ketone; or
(phenyl)-(1,2,3,4-tetrahydroisoquinolin-2-ylsulphonylmethyl)-ketone; ~~and with the proviso that~~ when R^2 and R^3 are hydrogen, m is 0, and Ring B is 4-methylpiperazin-1-yl, then $(R^1)_n$ is not hydrogen, 4-fluoro, 4-nitro, 3,4-dimethoxy, 4-methoxy, 4-*t*-butyl, 4-trifluoromethyl, or 4-chloro; and ~~with the proviso that~~
when R^2 and R^3 are hydrogen, m is 0, and Ring B is morpholino, then $(R^1)_n$ is not hydrogen, 4-dimethylamino, 4-nitro, 4-methoxy, 4-*t*-butyl, 4-trifluoromethyl, or 4-fluoro or 4-chloro.

12. (Currently Amended) A compound of formula (Ik):



(Ik)

wherein:

$\mathbf{R^1}$ is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-6}alkylene-Y-, and heterocyclylC_{0-6}alkylene-Y-; or
two R^1 groups on adjacent carbons may form an oxyC_{1-4}alkoxy group or a C_{3-5}alkylene group; wherein R^1 may be optionally substituted on carbon ~~by~~ with one or more R^7 groups ~~selected from R^7~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^8 group ~~selected from R^8~~;

n is 0-3; wherein the values of R^1 may be the same or different;

$\mathbf{R^2}$ and $\mathbf{R^3}$ are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2,

C_{1-4}alkoxycarbonyl, C_{1-4}alkoxycarbonylamino, C_{1-4}alkanoyloxy, carbocyclyl, heterocyclyl, carbocyclylC_{1-4}alkyl, and heterocyclylC_{1-4}alkyl; or

R^2 and R^3 together form oxo or a spiro attached heterocyclyl; wherein R^2 and R^3 may be independently optionally substituted on carbon ~~by~~ with one or more R^9 groups ~~selected from R^9~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{10} group ~~selected from R^{10}~~;

Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{17} group ~~selected from R^{17}~~;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{0-4}alkylene-Y-, and heterocyclylC_{0-4}alkylene-Y-; wherein R^6 may be optionally substituted on carbon ~~by~~ with one or more R^{18} groups ~~selected from R^{18}~~; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted ~~by~~ with an R^{19} group ~~selected from R^{19}~~;

m is 0-3; wherein the values of R^6 may be the same or different;

Y is -S(O)$_a$-, -O-, -NR^{20}-, -C(O)-, -C(O)NR^{21}-, -NR^{22}C(O)-, or -SO$_2$NR^{23}-; wherein a is 0 to 2;

R^7, R^9, and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl, *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl, C_{1-4}alkylsulphonylamino, carbocyclyl, and heterocyclyl; wherein R^7, R^9, and R^{18} may be independently optionally substituted on carbon ~~by~~ with one or more R^{26} groups;

R^8, R^{10}, R^{17}, and R^{19} are independently selected from C_{1-4}alkyl, C_{1-4}alkanoyl, C_{1-4}alkylsulphonyl, C_{1-4}alkoxycarbonyl, carbamoyl, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl, carbocyclyl, heterocyclyl, and

phenylsulphonyl; wherein R^8, R^{10}, R^{17}, and R^{19} may be independently optionally substituted on carbon ~~by~~ with one or more R^{27} groups;

R^{16}, R^{20}, R^{21}, R^{22}, and R^{23} are independently selected from hydrogen, phenyl, C_{1-4}alkylsulphonyl, and C_{1-4}alkyl;

R^{26} and R^{27} are independently selected from selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, and ~~or~~ *N*-methyl-*N*-ethylsulphamoyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not

(phenyl)-(5-methylpyrazol-3-ylaminosulphonylmethyl)-ketone;

(phenyl)-[(2-methyl-6-methoxy-2,3-dihydrobenzofuran-4-yl)aminosulphonylmethyl]-ketone;

(phenyl)-(1-phenyl-3-methylpyrazol-5-ylaminosulphonylmethyl)-ketone;

(phenyl)-[1-(cyclohexyl-*N*-methylaminosulphonyl)ethyl]-ketone;

(phenyl)-[1-(phenyl-*N*-methylaminosulphonyl)ethyl]-ketone;

(phenyl)-(cyclohexylaminosulphonylmethyl)-ketone;

(phenyl)-[(2-phenyl-4-acetyl-5-methylimidazol-3-yl]-*N*-methylaminosulphonylmethyl]-ketone;

(phenyl)-[(2-phenyl-4-acetyl-5-methylimidazol-3-yl]aminosulphonylmethyl]-ketone;

(phenyl)-(2,4,5,6,7,8-hexahydrocycloheptapyrazol-3-ylaminosulphonylmethyl]-ketone;

(phenyl)-(4,5,6,7-tetrahydro-2H-indazol-3-ylaminosulphonylmethyl]-ketone;

(phenyl)-[(4-phenyl-5-methylpyrazol-3-yl)aminosulphonylmethyl]-ketone;

(phenyl)-[3-(1-carboxymethyl-3-methyl-4-oxo-1,2,3,4-tetrahydrophthalazin-2-yl)anilinosulphonylmethyl]-ketone;

(phenyl)-{3-[1-(methoxycarbonylmethyl)-3-methyl-4-oxo-1,2,3,4-tetrahydrophthalazin-2-yl]anilinosulphonylmethyl}-ketone; (phenyl)-(4-methylanilinosulphonylmethyl)-ketone;

(phenyl)-(2-benzoyl-4-chloroanilinosulphonylmethyl)-ketone;

(phenyl)-(2,3-dimethylanilinosulphonylmethyl)-ketone;

(phenyl)-(3,4-dimethylanilinosulphonylmethyl)-ketone;

(phenyl)-(3-methylanilinosulphonylmethyl)-ketone;
(phenyl)-(3-methoxyanilinosulphonylmethyl)-ketone;
(phenyl)-(anilinosulphonylmethyl)-ketone; (phenyl)-(2-acetylanilinosulphonylmethyl)-ketone; or (phenyl)-[α-(*N*-ethylanilinosulphonyl)benzyl]-ketone.

13. (Currently Amended) A pharmaceutical composition which comprises a compound of ~~formula (I), (Ij) or (Ik), or a pharmaceutically acceptable salt thereof, as claimed in~~ any one of claims 9, 11 or 12, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically[[-]] acceptable diluent or carrier.

14. (Currently Amended) A ~~compound of the formula (I), (Ij) or (Ik), or a pharmaceutically acceptable salt thereof, as claimed in~~method for inhibiting 11βHSD1, comprising administering to a warm-blooded animal, a therapeutically effective amount of a compound of any one of claims 9, 11, or 12~~, for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man~~.

15-16. (Cancelled).

17. (Currently Amended) A method for the treatment of a metabolic syndrome, comprising inhibiting 11βHSD1~~The use of a compound~~ as claimed in ~~any one of claims~~ claim 1~~-8~~, or 10~~ or 16 wherein production of, or producing an, 11βHSD1 inhibitory effect refers to the treatment of metabolic syndrome~~.

18. (Currently Amended) A method for the treatment of a disease selected from~~The use of a compound as claimed in any one of claims 1-8, 10 or 16 wherein production of, or producing an, 11βHSD1 inhibitory effect refers to the treatment of~~ diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia, and ~~or~~ hypertension, comprising inhibiting 11βHSD1 as claimed in claim 1 or 10~~particularly diabetes and obesity~~.

19. (Currently Amended) A method for the treatment of a disease selected from~~The use of a compound as claimed in any one of claims 1-8, 10 or 16 wherein production of, or producing an, 11βHSD1 inhibitory effect refers to the treatment of~~ glaucoma, osteoporosis, tuberculosis,

dementia, cognitive disorders or depression, comprising inhibiting 11βHSD1 as claimed in claim 1 or 10.

20. (Cancelled).

Application No.: Not Yet Assigned Docket No.: ASZD-P01-804

REMARKS

The specification was amended to add the priority applications and insert the abstract into the specification. Claims 1-14 and 17-19 were amended and claims 15, 16, and 20 were canceled in order to reduce the number of claims. No new matter was added by these amendments.

CONCLUSION

The Commissioner is hereby authorized to credit any overpayment or charge any deficiency in the fees filed, to our Deposit Account No. 18-1945, under Order No. ASZD-P01-804. Please direct any questions arising from this submission to the undersigned at (617) 951-7615.

Respectfully Submitted,

Date: January 24, 2005

Customer No: 28120
Ropes & Gray LLP
One International Place
Boston, MA 02110
Phone: 617-951-7615
Fax: 617-951-7050

David P. Halstead, Ph.D.
Reg. No: 44,735

Application No.: Not Yet Assigned Docket No.: ASZD-P01-804

ABSTRACT

KETONES



(I)

Compounds of formula (I): wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

100804-1P US

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

KETONES

the specification of which:

☐ is attached hereto.

OR

☐ was filed on _____ with Express Mail No. (Application Number not yet known).

OR

☒ was filed on 23 July 2003 as United States Application Number or PCT International Application Number PCT/GB2003/003171 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. Serial No.	Filing Date	Status

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Serial No.	Filing Date	Status

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
GB	0217433.2	27 July 2002	☒ Yes ☐ No
GB	0230318.8	24 December 2002	☒ Yes ☐ No

I hereby appoint all registered practitioners associated with **Customer Number 28120** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

Customer Number 28120

Direct all telephone calls to PATRICIA GRANAHAN, Reg. No. 32,227, at telephone number (617) 951-7449.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Peter John BARTON

Inventor's Signature: _____ Date: 15/12/04

Residence Address: Macclesfield, Cheshire, Great Britain

Citizenship: GB

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, Great Britain SK10 4TG

Full Name of Inventor: David Stephen CLARKE

Inventor's Signature: David S Clarke Date: 15-12-04

Residence Address: Macclesfield, Cheshire, Great Britain

Citizenship: GB

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, Great Britain SK10 4TG

Full Name of Inventor: Christopher Daniel DAVIES

Inventor's Signature: _____ Date: 17-12-04

Residence Address: Macclesfield, Cheshire, Great Britain

Citizenship: GB

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, Great Britain SK10 4TG

Full Name of Inventor: Rodney Brian HARGREAVES

Inventor's Signature: _____ Date: 21/12/04

Residence Address: Macclesfield, Cheshire, Great Britain

Citizenship: GB

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, Great Britain SK10 4TG

Full Name of Inventor: Janet Elizabeth PEASE

Inventor's Signature: _____ Date: 17-12-04

Residence Address: Macclesfield, Cheshire, Great Britain

Citizenship: GB

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, Great Britain SK10 4TG

Full Name of Inventor: Maureen Theresa RANKINE

Inventor's Signature: _____ Date: 16/12/04

Residence Address: Macclesfield, Cheshire, Great Britain

Citizenship: GB

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, Great Britain SK10 4TG